10.1371/journal.pone.0155635.g003
Tetsuya Tsujikawa
Tetsuya
Tsujikawa
Satoko Asahi
Satoko
Asahi
Myungmi Oh
Myungmi
Oh
Yoshitaka Sato
Yoshitaka
Sato
Norihiko Narita
Norihiko
Narita
Akira Makino
Akira
Makino
Tetsuya Mori
Tetsuya
Mori
Yasushi Kiyono
Yasushi
Kiyono
Tatsuro Tsuchida
Tatsuro
Tsuchida
Hirohiko Kimura
Hirohiko
Kimura
Shigeharu Fujieda
Shigeharu
Fujieda
Hidehiko Okazawa
Hidehiko
Okazawa
Kaplan-Meier curves of progression-free survival (PFS) for <sup>62</sup>Cu-ATSM PET (a) and <sup>18</sup>F-FDG PET (b) in patients with HNC.
Public Library of Science
2016
18 F-FDG
threshold
TMR ATSM
SUV ATSM
ROC analysis
RTV
CSS
18 F-FDG PET scans
PSF
62 Cu-ATSM PET
18 F-FDG PET
62 Cu-ATSM
Tumor Redox Status
HNC patient outcomes
TLR
TLG
tumor-to-muscle activity concentration ratios
62 Cu-ATSM PET Purpose Tumor redox
MTV
II
PFS
Conclusion Tumor redox parameters
pretreatment 62 Cu-ATSM
2016-05-17 21:18:42
Figure
https://plos.figshare.com/articles/figure/Kaplan-Meier_curves_of_progression-free_survival_PFS_for_sup_62_sup_Cu-ATSM_PET_a_and_sup_18_sup_F-FDG_PET_b_in_patients_with_HNC_/3939063
<p>Two groups of high (dotted lines) and low (solid lines) tracer accumulation were determined by each cut-off value of the tumor-to-muscle ratios (TMR<sub>ATSM</sub> and TMR<sub>FDG</sub>). TMR<sub>ATSM</sub>, one of the intensity-based redox parameters, showed a significant difference in PFS between two groups (<i>p</i> = 0.03), whereas TMR<sub>FDG</sub>, one of the intensity-based metabolic parameters, did not (<i>p</i> = 0.15). The three-year PFS rate was 74% for patients with lower accumulation tumors (TMR<sub>ATSM</sub> ≤ 3.2) and 29% for those with over-reductive tumors (TMR<sub>ATSM</sub> > 3.2).</p>